Key facts
- This page summarizes David Carl Humphrey's Form 4 filing for Ensysce Biosciences, Inc. (ENSC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2022, 18:05.
David Carl Humphrey - 17 Feb 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ENSC
- Reported as of
- 17 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2022, 18:05:03 UTC
- Prior SEC filing
- 04 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Carl Humphrey
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Carl Humphrey filed Form 4 for Ensysce Biosciences, Inc. (ENSC) on 24 Feb 2022.
Change
- Previous filing in this sequence was filed on 04 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +80,000
- Change %
- Price
- Shares after
- 80,000
- Date
- 17 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $1.40
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.